Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

TCT 2021 | HSCT & CAR-T therapy during COVID-19: Chinese experience

He Huang • 2 Feb 2021
TCT 2021
General

He Huang, MD, PhD, Zhejiang University, Hangzhou, China, outlines the impact of the COVID-19 pandemic on haploidentical stem cell transplantation (HSCT) and CAR T-cell therapy in China. Prof. Huang outlines infrastructure changes in response to the pandemic and provides an overview of the management strategies implemented for patients with hematological malignancies during the COVID-19 pandemic as well as changes in care following HSCT. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.

More from He Huang

3:09
An update on the experience with CAR T-cell therapy in China
He Huang • 16 Feb 2024
4:17
Novel CAR T-cell therapies for hematological malignancies: exploring new targets
He Huang • 16 Feb 2024
1:19
Managing CRS after anti-BCMA CAR-T for myeloma
He Huang • 17 May 2019
2:37
CAR-T cells for myeloma: experience from China
He Huang • 16 May 2019

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals